Health✓ Verified

Common antidepressant may ease long COVID's crushing fatigue

Reported byScienceDaily ↗·Sourced by Goodlede

What backs it

A randomized clinical trial of 399 adults found fluvoxamine, an inexpensive antidepressant already in common use, significantly reduced long COVID fatigue and improved quality of life compared to placebo, with 99% statistical confidence in the medication's superiority. The trial across Canada, Brazil, and the US was published in Annals of Internal Medicine.

Worth noting

Clinical translation remains future research.

Systemic / trendWell established✓ Verified

Goodlede runs a two-pass source check on every story: one pass finds it, a second skeptical pass re-verifies the claim and writes what it doesn’t prove. This is a source check, not an independent fact-check — confirm anything important at the link above.

Read the full story at ScienceDaily

Read original story ↗

Common antidepressant may ease long COVID's crushing fatigue

More good news, verified daily.